Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutic (NQ: UTHR )

243.82 +9.49 (+4.05%)
Streaming Delayed Price Updated: 9:51 AM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about United Therapeutic

< Previous 1 2 3 Next >
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
CORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
From United Therapeutics Corporation
Via Business Wire
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
Liquidia: Court victory the awakening of an industry giant?
Liquidia's stock surged after an enormous court win against United Therapeutics, accompanied by analyst upgrades and insider buying. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger
From United Therapeutics Corporation
Via Business Wire
United Therapeutics and Miromatrix Medical Announce Successful Tender Offer
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2024
From United Therapeutics Corporation
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eargo, Inc. (Nasdaq – EAR), Miromatrix Medical, Inc. (Nasdaq – MIRO), Physicians Realty Trust (NYSE – DOC), Spirit Realty Capital (NYSE – SRC)
From Brodsky & Smith LLC
Via GlobeNewswire
United Therapeutics Corporation Reports Third Quarter 2023 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Announces First Patient Enrolled in Phase 3 TETON PPF Study of Nebulized Tyvaso in Patients with Progressive Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the UBS Biopharma Conference 2023
From United Therapeutics Corporation
Via Business Wire
United Therapeutics to Acquire Miromatrix Medical
From Miromatrix Medical Inc.
Via GlobeNewswire
United Therapeutics to Acquire Miromatrix Medical
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report Third Quarter 2023 Financial Results Before the Market Opens on Wednesday, November 1, 2023
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Announces Recent Milestones for its Heart and Kidney Xenotransplantation Programs
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Issues its 2023 Corporate Responsibility and Public Benefit Report
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Reports Second Quarter 2023 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report Second Quarter 2023 Financial Results Before the Market Opens on Wednesday, August 2, 2023
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Wins Appeal in Dry Powder Inhaler Patent Litigation
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Unveils Net Zero Energy Distribution Center
From United Therapeutics Corporation
Via Business Wire
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
Exposures Product Safety
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.